首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal Study
【24h】

Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal Study

机译:同种异体造血干细胞移植术后托奎病毒动力学和免疫标志性能:透视纵向研究

获取原文
获取原文并翻译 | 示例
           

摘要

Torquetenovirus (TTV) has been proposed as a marker of immune function in patients receiving immunosuppression after solid organ transplantation. This study aimed to define TTV plasma dynamics and investigate clinical associations in patients following allogeneic hematopoietic stem cell transplantation (HSCT). This wasa single-center prospective longitudinal study involving 50 consecutive patients treated with HSCT between March 2015 and April 2016. TTV plasma DNA levels were measured with quantitative PCR at 12 consecutive ime points during the first year after HSCT. Forty of the 50 patients (80%) had detectable TTV viremia before HSCT (median level, 5.37 log10 copies/mL; interquartile range [IQR], 3.51-6.44 log10 copies/mL). All patients subsequently developed TTV viremia during the follow-up period. Plasma viral loads evolved dynamically over time, with a peak of 8.32 log10 copies/mL (IQR, 7.33-9.35 log10 copies/mL) occurring at 79 days (IQR, 50- 117 days) following HSCT and a stable plateau toward the d of the follow-up period. The type of malignancy, the use of antithymocyte globulin during conditioning, and the occurrence of acute graft-versus-host disease requiring systemic therapy had temporary effects on TTV dynamics. TTV levels showed a significant correlation with absolute lymphocyte counts following engraftment (rs = -.27; P < .01) and with cytomegalovirus (CMV; rs = .39; P < .01) and Epstein-Barr virus (EBV; rs = .45; P = .02) viral loads during phases of viremia. Immunerelated clinical events were not predicted by TTV levels. TTV viremia occurred universally and was sustained throughout the first year after HSCT. Several variables and events before and after HSCT were correlated with TTV levels and hint toward immune marker properties of TTV, but their complex interactions might perturb the capability of TTV to predict immune-related complications in this population
机译:已经提出了托奎吞病毒(TTV)作为在固体器官移植后接受免疫抑制患者免疫功能的标志物。本研究旨在定义TTV等离子体动力学,并调查同种异体造血干细胞移植(HSCT)后患者的临床关联。这项涉及2015年3月至2016年3月至2016年3月至2016年3月间在HSCT期间治疗的50名连续50名患者。在HSCT后的第一年的连续IME点,用定量PCR测量TTV血浆DNA水平。 50例患者(80%)在HSCT之前有可检测的TTV病毒血症(中位数,5.37 log10拷贝/ ml;四分位数范围[IQR],3.51-6.44 log10副本/ ml)。所有患者随后在随后在随访期间开发了TTV病毒血症。血浆病毒载荷随时间动态演变,在HSCT后79天(IQR,50-117天)发生8.32 log10拷贝/ ml(IQR,7.33-9.35个log10拷贝/ ml)的峰值和稳定的高原随访期。恶性肿瘤的类型,在调理过程中使用抗癌细胞球蛋白,以及需要全身治疗的急性移植物与宿主疾病的发生对TTV动力学产生暂时的影响。 TTV水平显示与植入后的绝对淋巴细胞计数显着相关(Rs = -27; p <.01)和缩细胞病毒(CMV; rs = .39; p <.01)和epstein-barr病毒(EBV; RS = .45; p = .02)病毒血症阶段的病毒载荷。 TTV水平未预测免疫型临床事件。 TTV遗体均普遍发生,并在HSCT后的第一年持续。 HSCT之前和之后的几种变量和事件与TTV水平相关,并提示朝TTV的免疫标记性质相关,但它们的复杂相互作用可能会扰乱TTV能力预测这种人群中的免疫相关并发症

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号